First Header Logo Second Header Logo

Connection

Elsayed Soliman to Antihypertensive Agents

Back to Details
This is a "connection" page, showing publications Elsayed Soliman has written about Antihypertensive Agents.
Elsayed Soliman
Connection Strength
4.567
Antihypertensive Agents
  1. Soliman EZ, Rahman AF, Zhang ZM, Rodriguez CJ, Chang TI, Bates JT, Ghazi L, Blackshear JL, Chonchol M, Fine LJ, Ambrosius WT, Lewis CE. Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation. Hypertension. 2020 06; 75(6):1491-1496.
    View in: PubMed
    Score: 0.585
  2. Soliman EZ, Prineas RJ. Antihypertensive Therapies and Left Ventricular Hypertrophy. Curr Hypertens Rep. 2017 Sep 19; 19(10):79.
    View in: PubMed
    Score: 0.487
  3. Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, Carson TY, Tamariz L, Ghazi L, Cho ME, Shapiro BP, He J, Fine LJ, Lewis CE. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017 Aug 01; 136(5):440-450.
    View in: PubMed
    Score: 0.476
  4. Chen LY, Bigger JT, Hickey KT, Chen H, Lopez-Jimenez C, Banerji MA, Evans G, Fleg JL, Papademetriou V, Thomas A, Woo V, Seaquist ER, Soliman EZ. Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. Am J Hypertens. 2016 11 01; 29(11):1276-1282.
    View in: PubMed
    Score: 0.459
  5. Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC, Chen H. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015 Dec; 66(6):1123-9.
    View in: PubMed
    Score: 0.426
  6. Ahmad MI, Kazibwe R, Soliman MZ, Singh S, Chen LY, Soliman EZ. Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy. Am J Cardiol. 2023 Dec 01; 208:75-82.
    View in: PubMed
    Score: 0.185
  7. Garg PK, Wilson N, Yuan Y, Howard VJ, Judd S, Howard G, Soliman EZ. Association of hypertension severity and control with risk of incident atrial fibrillation: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Clin Cardiol. 2023 Nov; 46(11):1418-1425.
    View in: PubMed
    Score: 0.184
  8. Soliman EZ, Mills KT. Exploring the Relationship Between Intensive Blood Pressure Lowering, Left Ventricular Hypertrophy, and Cardiovascular Outcomes. Hypertension. 2023 Sep; 80(9):1843-1844.
    View in: PubMed
    Score: 0.183
  9. Frimodt-Møller EK, Vittinghoff E, Kaur G, Biering-Sørensen T, Soliman EZ, Marcus GM. Association Between Intensive vs Standard Blood Pressure Control and Incident Left Ventricular Conduction Disease: A Post Hoc Analysis of the SPRINT Randomized Clinical Trial. JAMA Cardiol. 2023 Jun 01; 8(6):612-616.
    View in: PubMed
    Score: 0.181
  10. Kamel H, Rahman AF, O'Neal WT, Lewis CE, Soliman EZ. Effect of intensive blood pressure lowering on left atrial remodeling in the SPRINT. Hypertens Res. 2021 10; 44(10):1326-1331.
    View in: PubMed
    Score: 0.159
  11. Brooks JE, Soliman EZ, Upadhya B. Is Left Ventricular Hypertrophy a Valid Therapeutic Target? Curr Hypertens Rep. 2019 05 20; 21(6):47.
    View in: PubMed
    Score: 0.137
  12. Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, Simpson LM, Haywood LJ, Marcus GM. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Circ Arrhythm Electrophysiol. 2017 Dec; 10(12).
    View in: PubMed
    Score: 0.124
  13. Haywood LJ, Davis BR, Piller LB, Simpson LM, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. J Natl Med Assoc. 2018 Aug; 110(4):343-351.
    View in: PubMed
    Score: 0.121
  14. Haywood LJ, Davis BR, Piller LB, Cushman WC, Cutler JA, Ford CE, Simpson LM, Ghosh A, Soliman EZ, Wright JT. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. J Natl Med Assoc. 2017 Autumn; 109(3):172-181.
    View in: PubMed
    Score: 0.118
  15. Ernst ME, Davis BR, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, Cushman WC, Einhorn PT, Oparil S, Grimm RH. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Am Soc Hypertens. 2016 12; 10(12):930-938.e9.
    View in: PubMed
    Score: 0.115
  16. Dewland TA, Soliman EZ, Davis BR, Magnani JW, Yamal JM, Piller LB, Haywood LJ, Alonso A, Albert CM, Marcus GM. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. JAMA Intern Med. 2016 08 01; 176(8):1085-92.
    View in: PubMed
    Score: 0.113
  17. Bhatt H, Gamboa CM, Safford MM, Soliman EZ, Glasser SP. Prevalence of electrocardiographic abnormalities based on hypertension severity and blood pressure levels: the Reasons for Geographic and Racial Differences in Stroke study. J Am Soc Hypertens. 2016 09; 10(9):702-713.e4.
    View in: PubMed
    Score: 0.112
  18. O'Neal WT, Soliman EZ, Qureshi W, Alonso A, Heckbert SR, Herrington D. Sustained pre-hypertensive blood pressure and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. J Am Soc Hypertens. 2015 Mar; 9(3):191-6.
    View in: PubMed
    Score: 0.101
  19. Ernst ME, Neaton JD, Grimm RH, Collins G, Thomas W, Soliman EZ, Prineas RJ. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011 Dec; 58(6):1001-7.
    View in: PubMed
    Score: 0.081
  20. Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med. 2011 Jan; 52(1):10-5.
    View in: PubMed
    Score: 0.075
  21. Ascher SB, de Lemos JA, Lee M, Wu E, Soliman EZ, Neeland IJ, Kitzman DW, Ballantyne CM, Nambi V, Killeen AA, Ix JH, Shlipak MG, Berry JD. Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy. J Am Coll Cardiol. 2022 Oct 18; 80(16):1516-1525.
    View in: PubMed
    Score: 0.043
  22. Costa MD, Redline S, Soliman EZ, Goldberger AL, Heckbert SR. Fragmented sinoatrial dynamics in the prediction of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. Am J Physiol Heart Circ Physiol. 2021 01 01; 320(1):H256-H271.
    View in: PubMed
    Score: 0.038
  23. Rattani A, Claxton JS, Ali MK, Chen LY, Soliman EZ, Alvaro A. Association and impact of hypertension defined using the 2017 AHA/ACC guidelines on the risk of atrial fibrillation in The Atherosclerosis Risk in Communities study. BMC Cardiovasc Disord. 2019 11 26; 19(1):262.
    View in: PubMed
    Score: 0.035
  24. Bang CN, Soliman EZ, Simpson LM, Davis BR, Devereux RB, Okin PM. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. Am J Hypertens. 2017 Sep 01; 30(9):914-922.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.